Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Retrophin Inc (RTRX) A Good Stock To Buy?

Page 1 of 2

Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap stocks. There is little or no publicly-available information at all on some of these small companies, which makes it hard for an individual investor to pin down a winner within the small-cap space. However, hedge funds and other big asset managers can do the due diligence and analysis for you instead, thanks to their highly-skilled research teams and vast resources to conduct an appropriate evaluation process. Looking for potential winners within the small-cap galaxy of stocks? We believe following the smart money is a good starting point.

Retrophin Inc (NASDAQ:RTRX) shareholders have witnessed an increase in hedge fund interest recently. RTRX was in 23 hedge funds’ portfolios at the end of September. There were 18 hedge funds in our database with RTRX holdings at the end of the previous quarter. At the end of this article we will also compare RTRX to other stocks including Rent-A-Center Inc (NASDAQ:RCII), SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN), and Triangle Capital Corporation (NYSE:TCAP) to get a better sense of its popularity.

Follow Retrophin Inc. (NASDAQ:RTRX)
Trade (NASDAQ:RTRX) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

RAJ CREATIONZS / shutterstock.com

What does the smart money think about Retrophin Inc (NASDAQ:RTRX)?

At Q3’s end, a total of 23 of the hedge funds tracked by Insider Monkey held long positions in this stock, a 28% increase from the second quarter of 2016. Hedge funds have been consistently buying into and then selling out of the stock over the past year, creating a W-shaped ownership chart. With hedgies’ positions undergoing their usual ebb and flow, there exists an “upper tier” of notable hedge fund managers who were boosting their holdings substantially (or already accumulated large positions).
RTRX
According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Matt Sirovich and Jeremy Mindich’s Scopia Capital has the biggest position in Retrophin Inc (NASDAQ:RTRX), worth close to $95.2 million, accounting for 1.7% of its total 13F portfolio. The second largest stake is held by Broadfin Capital, led by Kevin Kotler, holding a $77.6 million position; the fund has 7% of its 13F portfolio invested in the stock. Other professional money managers that are bullish comprise Mitchell Blutt’s Consonance Capital Management, Joseph Edelman’s Perceptive Advisors and Israel Englander’s Millennium Management.

Page 1 of 2
Loading Comments...